Survival in adult patients with low-grade brain tumors has improved
the ONA take:
Outcomes for patients with low-grade gliomas have improved significantly in recent years, according to an analysis of clinical data collected from a US cancer registry over the past decade. Low-grade gliomas are a slow-growing yet deadly primary brain cancer. In addition, management strategies, including when and whether to administer radiation, what type of surgery to perform, and what type of chemotherapy to administer, vary widely among physicians.
A research team at University of California San Diego School of Medicine used the Surveillance, Epidemiology, and End Results (SEER) database to demonstrate that median survival for patients with low-grade gliomas increased from 44 months (in 1999) to 57 months (in 2010).
The study suggests the improved survival may be due to more effective chemotherapies used to treat the disease. The researchers noted that survival improved despite a reduction in the use of radiation therapy when low-grade glioma is first diagnosed. Only approximately one-third of US patients underwent complete excision, a rate that remained unchanged throughout the past decade despite the procedure being associated with longer patient survival.
Survival in adult patients with low-grade brain tumors has improved.
Researchers at the University of California, San Diego School of Medicine demonstrated that significant strides have been made in improving the survival of adult patients with low-grade gliomas.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|